title: Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors.
abstract: Psoriasis is a common, chronic and disabling skin disorder affecting approximately 2% of the population, associated with significant negative impact on the patient's quality of life. Approximately 80% of those affected with psoriasis have mild-to-moderate forms and are usually treated with topical therapy, whereas phototherapy and systemic therapies are used for those with severe disease. In the past three decades, the major advances in psoriasis therapy have been in systemic agents for the treatment of moderate-to-severe psoriasis, particularly new immunomodulatory and biological molecules, while topical therapies have remained relatively unchanged over the past decades. Indeed, topical corticosteroids and vitamin D3 analogs are still the gold standard of therapy for mild-to-moderate psoriasis. Thus, there is a need to develop new and more effective topical agents in the short and long term, with a better efficacy and safety profile than corticosteroids and vitamin D3 analogs. Over the past five years, investigation into topical therapy has expanded, with exciting new drugs being developed. Preliminary results of these emerging agents that selectively target disease-defining pathogenic pathways seem to be promising, although long-term and large-scale studies assessing safety and efficacy are still lacking. The aim of this article was to review the clinical and research data of some emerging topical agents, focusing on Janus kinase-signal transducer and activator of transcription and phosphodiesterase type 4 inhibitors, which are currently being investigated.
authors.affiliation: USF Sete Caminhos - ACeS Gondomar.
authors.forename: Adilia
authors.initials: A
authors.lastname: Rafael
authors.affiliation: Department of Dermatology, Centro Hospitalar do Porto, Rua D. Manuel II, s/n, 4099-001 Porto, Portugal, Unit for Multidisciplinary Research in Biomedicine, Instituto Ciências Biomédicas Abel Salazar, University of Porto, Portugal.
authors.forename: Tiago
authors.initials: T
authors.lastname: Torres
mesh_terms: D003879:Dermatologic Agents / Q000627:therapeutic use; D006801:Humans; D053613:Janus Kinase 1 / Q000037:antagonists & inhibitors*; D058988:Phosphodiesterase 4 Inhibitors / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D003879:Dermatologic Agents; D058988:Phosphodiesterase 4 Inhibitors; D053613:Janus Kinase 1
keywords: JAK/STAT inhibitors; phosphodiesterase-4 inhibitors; psoriasis; small molecules; topical therapy